

Founder of the Hong Kong Bing BioTech Limited Wong Bing-Lou

Wong Bing-Lou, from Hong Kong, graduated from the Department of Chemical Engineering at National Taiwan University in 1972. He then went to Tufts University School of Medicine in Boston, USA for further studies and obtained his Master's and Doctoral degrees in Chemical Engineering. He is now the founder of Hong Kong Bing BioTech Limited and a visiting professor at the School of Life Sciences at The Chinese University of Hong Kong.

Wong Bing-Lou was appointed as a member of the Overseas Chinese Affairs Commission of the Republic of China from 1991 to 2000. In 1992, he was awarded the first "Model of Entrepreneurs Awards" by the Republic of China. In 2001, he received the Outstanding Service Award from Bunker Hill Community College in Boston, Massachusetts, recognizing his contributions to the Asian community in Boston.

Wong Bing-Lou has performed outstandingly in the field of biotechnology, with over 40 years of experience in the development of biotech protein therapy. He has obtained over 100 patents and is the licensee for several world leading companies such as Roche and TEVA Pharmaceutical Industries. His products include medicines for both human and animal use.

Wong Bing-Lou has performed outstandingly in the field of biotechnology, with over 40 years of experience in the development of biotech protein therapy. He has obtained over 100 patents and is the licensee for several world leading companies such as Roche and TEVA Pharmaceutical Industries. His products include medicines for both human and animal use.

Wong Bing-Lou has made outstanding contributions to the research of artificial blood. To start the remarkable story of why he ventured into the field of artificial blood research, we go back to 1985. His team successfully purified one liter of hemoglobin within a week and injected it into laboratory animals without causing death or noticeable side effects. This accomplishment earned them a \$500,000 funding to establish a biotechnology company, marking a new milestone in artificial blood research.

The animal medicine Oxyglobin (a hemoglobin solution without a matrix) developed by the company was approved for sale by the US Food and Drug Administration and the European Medicines Agency in 1999-2000. It is used to treat severe hemorrhage and acute anemia in dogs and household pets. The human medicine Hemopure (bovine hemoglobin polymer) was first approved in South Africa in 2001 and received approval in Russia in 2011. In 2021, the US Food and Drug Administration agreed to assist the US Army in restarting Phase III clinical trials in South Africa.

In 2018, Hong Kong Advantek Serum Laboratories Limited developed a new biopharmaceutical production technology, which obtained three US patents and one Taiwan patent. Founded in 2019, Hong Kong Radiant BioTech Limited provides a platform for young scientists to achieve their dreams. Currently, the company is conducting research on alcohol metabolism and developing it into a new commercial product. Additionally, they are also involved in researching other biological agents. In 2019, amidst the global spread of COVID-19, the research team led by Huang Bingliao actively participated in vaccine development, offering the ability to combat the virus.

Wong Bing-Lou has performed outstandingly in the field of biotechnology. He has led a team in the research and development of products for both human and veterinary medicine, benefiting both humans and animals. His achievements have been widely acknowledged both domestically and internationally, and his unwavering dedication is admirable. He serves as an exemplary figure in the field of biotechnology.